AB Science Release: Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology

Published: Jun 13, 2012

PARIS--(BUSINESS WIRE)--AB Science SA (Paris:AB)(NYSE-Euronext-FR0010557264-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis. The article, ‘Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study’, is freely accessible online from BioMed Central's peer-reviewed journal BMC Neurology (http://www.biomedcentral.com/1471-2377/12/36/abstract).

Back to news